News Release:June 20 2018
Dr Yeates will be co-chairing the session on Formulation and Smart DDS (Drug Delivery Science) and presenting "Delivery of Aerosolized Biologics at High Dose Rates" at " BIT's 16th Annual Congress of International Drug discovery Science and Technology", August 16-18, Boston, 2018
Just published online
Xin Heng & Donovan B. Yeates (2018) Generation of High Concentrations of Respirable Solid-Phase Aerosols from Viscous Fluids, Aerosol Science and Technology, DOI: 10.1080/02786826.2018.1488078
In the fall look for:
September 10-112018 KAER is Partner in DDF Summit, Drug delivery and Formulation, San Francisco
June 2018 KAER exhibited at Respiratory Drug Delivery, Tucson, AZ.
June 1, 2017
Dr. Yeates presented "Augmentation of the Generation, Processing and Delivery of Surfactant and Macromolecule Aerosols with Heliox", 21 ISAM-Congress, Santa Fe, NM, June 3-7, 2017.
May 3, 2017
KAER, a Start-Up Breakthrough Finalist, presented at Start-Up Stadium, BIO, San Diego, June 21, 2017 (convention.bio.org/startup/)
Dr. Yeates presented "Aerosol Surfactant Replacement Therapy for Patients with Acute Respiratory Distress Syndrome" at the Life Sciences Summit, New York, NY, November 2-3, 2016.
Dr. Yeates presented: "Generation of Respirable Particles from Surfactant Suspensions and Viscous Solutions at High Dose Rates", Drug Delivery to the Lungs, Edinburgh, UK, December 7-9, 2016.
April 30, 2016
A potential new treatment for Acute Respiratory Distress Syndrome and Acute Lung Injury (ARDS/ALI) has been developed using an aerosolized surfactant. KAER has incorporated a new patent-pending nozzle technology into its SUPRAER® aerosol delivery platform. For the first time, surfactant aerosols less than 4 microns in diameter, can be delivered at 2 mg/second. In conjunction with negative pressure ventilation or incorporation of this technology into a ventilator would facilitate the delivery of a therapeutically-needed 1 g of surfactant aerosol to the patient’s deep lung in 20 minutes. This surfactant is targeted at replacing the inflammation-induced inactivated surfactant in these critically ill patients and reversing the resultant hypoxemia by reducing the surface tension in the deep lung, opening alveoli, resolving excess lung fluid (edema), decreasing the work of breathing, and thus improving gas exchange. KAER is working toward reducing the present mortality of these syndromes to considerably less than the current 43%.
The SUPRAER technology can be used to aerosolize viscous solutions and suspensions of any drug. Using 20% solutions of polyvinylpyrrolidone, as a protein or drug surrogate, aerosols of less than 4 microns in diameter have been generated at output rates up to 4 mg/second. A typical 7-second inhalation would deliver up to 28 mg during each breath or a therapeutically-needed dose of up to 280 mg in just 10 breaths. This is game-changing for the rapid delivery of anti-infectives and anticancer agents to the lungs.
The final size of these drug aerosol particles can be tailored for optimum deposition in the lungs of small and large animals as well as humans. These new developments add to KAER’s worldwide intellectual property portfolio on aerosol generation and processing for respiratory drug delivery. A comprehensive set of data generated with KAER’s new nozzles incorporated into the SUPRAER platform was presented at the Respiratory Drug Delivery conference in Phoenix, AZ, April 18-19, 2016. e April 30, 2016
March 14, 2016
KAER exhibited at the Society of Toxicology in New Orleans, March 14-16, 2016.
November 15, 2015
KAER is a finalist for a 2016 Patrick Soon Shiong Innovation Award for its SUPRAER aerosol delivery technology.
National Heart Lung and Blood Institute of the National Institutes of Health award KAER Biotherapeutics a Phase I SBIR grant “Aerosol delivery of Surfactant for ARDS” commencing September 1, 2015.
Dr. Yeates, Principal Investigator of this project noted, “This important new technological innovation will also be applicable to treat other diseases of the lungs that require drugs whose efficacy depends on high doses being delivered in a short time. Short treatment times lead to better patient adherence, efficacy and improved heath care.”
October 13, 2015
KAER exhibited at the Association of Inhalation Toxicologist, Cambridge, UK, Oct 13-15, 2015.
March 20, 2015
KAER exhibited at the Society of Toxicology, San Diego, March 20-23 2015.
Dr. Yeates presented "Aerosol delivery of Biotherapeutics:New Technologies" at Drug Delivery Systems 2014, Suzhou, China.
September 22-24, 2014
KAER exhibited at the AIT-ISAM joint conference "Inhaled Medications from the Bench to the Bedside: Preclinical, Clinical and Technical Considerations for 'First in Human' and Beyond" Princeton, NJ, 2014.
May 4-8, 2014
KAER exhibited at the Respiratory Drug Delivery, Puerto Rico.
March 23-25, 2014
KAER exhibited at the Society of Toxicology Annual Meetin in Phoenix
September 11-12, 2013
Dr. Yeates presented, "A New Class of Aerosol Generation System for High Dose-Rate Aerosol Delivery of Biotherapeutics" at: Inhalation Drug Delivery, Berlin, Germany.
June 11, 2013
KAER presented at NHLBI San Diego Innovation Conference, San Diego, CA
Copyright KAER Biotherapeutics Corporation. All Rights Reserved